Rethinking in-hospital mortality in patients on haemodialysis: the role of frailty screening
Published
June 8, 2025
Paper ID
PAP-000250
Status
Published
DOI
10.65712/tmj.test000508
Advance Services
Abstract
Background: The cost of in-hospital mortality to health systems is substantial. Methods: Missing data were handled with multiple imputation. Results: 1629 participants were included (median age 37 years). Serious adverse events were rare and similar between groups. Conclusion: Residual confounding cannot be excluded.
References
1. Okafor I, Moreau G, et al. SGLT2 inhibitors and health-related quality of life. Diabetes Care. 2018;389(6):5-1576.
2. Herrera U, Nasser E, et al. A sepsis alert system and ventilator-free days. Eur Heart J. 2025;260(5):14-1024.
3. Rahman G, Kim U, et al. Continuous glucose monitoring and 30-day readmission. Ann Intern Med. 2013;86(9):352-1661.
4. Costa U, Ahmed C, et al. Pharmacist-led medication review and surgical site infection. Diabetes Care. 2025;270(10):152-1322.
5. Schmidt M, Lindqvist P, et al. SGLT2 inhibitors and acute kidney injury. Lancet. 2016;300(3):692-983.
6. Moreau J, Yilmaz M, et al. An enhanced recovery pathway and medication adherence. Diabetes Care. 2019;132(5):623-916.
7. Kim N, Kaur A, et al. Delayed cord clamping and medication adherence. Diabetes Care. 2012;366(10):86-1262.
8. Dubois U, Lindqvist S, et al. Delayed cord clamping and falls. Diabetes Care. 2017;215(8):495-1270.
Introduction
Practice around frailty screening varies widely between centres. Guidelines make only a weak recommendation on frailty screening. Earlier studies of frailty screening were small or single-centre.
Earlier studies of frailty screening were small or single-centre. in-hospital mortality remains a leading cause of avoidable harm among patients on haemodialysis.
Materials and Methods
We conducted a prospective cohort study across 4 centres between 2017 and 2021. Analyses were adjusted for age, sex and baseline severity.
Eligible participants were patients on haemodialysis. The primary outcome was in-hospital mortality, assessed blind to allocation.
Eligible participants were patients on haemodialysis. Missing data were handled with multiple imputation. We conducted a prospective cohort study across 6 centres between 2014 and 2023.
Results
Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.
in-hospital mortality occurred in 14% of the intervention group versus 22% of controls. in-hospital mortality occurred in 4% of the intervention group versus 33% of controls.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.46 (95% CI 0.47 to 0.71).
| Group | n | Events |
|---|---|---|
| Age ≥ 65 | 788 | 30 |
| Centre A | 638 | 44 |
| Age ≥ 65 | 160 | 90 |
| Age ≥ 65 | 628 | 27 |
| Age < 65 | 819 | 34 |
| Control | 520 | 75 |
| Centre A | 666 | 6 |
Values are n (%) unless stated otherwise.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.

Shown for patients on haemodialysis; error bars are 95% confidence intervals.
in-hospital mortality occurred in 22% of the intervention group versus 29% of controls. The adjusted odds ratio was 0.82 (95% CI 0.36 to 0.87). The adjusted odds ratio was 0.90 (95% CI 0.25 to 0.68). Serious adverse events were rare and similar between groups.
Discussion
Implementation will depend on staffing, cost and local protocols. Future work should test frailty screening in a pragmatic multicentre trial.
Implementation will depend on staffing, cost and local protocols. Future work should test frailty screening in a pragmatic multicentre trial.
Strengths include the sample size and blinded outcome assessment. These findings suggest that frailty screening is associated with better in-hospital mortality in patients on haemodialysis. Implementation will depend on staffing, cost and local protocols.
Strengths include the sample size and blinded outcome assessment. Future work should test frailty screening in a pragmatic multicentre trial. These findings suggest that frailty screening is associated with better in-hospital mortality in patients on haemodialysis.
Conclusions
Frailty screening is a reasonable option for patients on haemodialysis to improve in-hospital mortality.
Appendices
The statistical analysis plan is in the online supplement.